NEW YORK (GenomeWeb News) – Leerink Swann today upgraded shares of Fluidigm, noting a potentially multi-billion market opportunity for single-cell gene expression tools and the recent acquisition of DVS Sciences as drivers.

In a research note, Dan Leonard raised the rating on Fluidigm to Outperform from Market Perform, and maintained a $52 price target on the South San Francisco, Calif.-based firm's stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.